PRESENTED BY MEDVICA INT’L<br />“The electric thimble that detects signs of heart disease”<br />Ron Lazzarini – 970.227.1314 – firstname.lastname@example.org<br />
What is it?<br />FDA approved, CE-marked, and validated by nearly 100 papers in peer-reviewed journals<br />This device non-invasively measures endothelial function<br />Endothelial dysfunction is defined as either decreased bioavailability of nitric oxide (which is integral to endothelial health), or as an impairment of endothelium-dependent vasodilation<br />Systemic manifestations of endothelial dysfunction include: stroke/TIA’s, sudden death from myocardial infarction, renal failure, sleep apnea, erectile dysfunction, metabolic syndrome, claudication, and gangrene.<br />
How does it work?<br />Fingertip probes measure endothelial function<br />Device software automatically records and analyzes test results<br />15 minute test can be given by a tech while the patient waits for the doctor<br />
What are the benefits?<br /><ul><li>CPT coded (93923) for simple billing and minimal conflict with insurance companies
Increases office revenue while simultaneously increasing the patients’ quality of care and quality of life
Provides incremental data to better predict and treat patients at risk for CVD, patients who would otherwise go undetected.
More effectively monitor treatment for better patient outcomes.
Measures earliest signs of atherosclerosis, while it is still reversible
Monitors effectiveness of patients being treated for cardiac disease</li></li></ul><li>
Who is it for?<br />Patients who have one or more cardiac risk factors<br />Patients on medications – looking for response and non responders<br />Family members of patients diagnosed with CAD<br />
What’s the point?<br />Improved quality of patient care.<br />Better patient monitoring means improved cardiac health and fewer cardiac events.<br />Reduce healthcare costs. $28.6B per year is spent on treating patients with congestive heart failure. EndoPAT detects cardiac risk while it is still reversible.<br />Increase revenue for doctors. Private insurers reimburse up to $500 per test, adding to the bottom-line of the doctor’s office.<br />
How much does it cost?<br />IRS Section 179 allows businesses to immediately expense the first $250,000 of capital equipment purchased each year against current year net income.<br />
Return on investment<br /><ul><li>A unique, office-based, vascular health diagnostic tool at a very affordable price.
Four 20-minute endoPAT studies/month = breakeven
One study per day, profit is approx $3,300/month
Five studies per day, profit is approx $16,500/month
25 studies per day, profit is approx $82,500/month</li></li></ul><li>Why should I (the doctor) use it?<br />Diagnose patients who have low CRFs<br />Monitor drug response<br />Reimbursed by insurance<br />New revenue stream<br />
Conclusions<br />EndoPAT 2000 provides incremental data to better predict and treat patients at risk for Cardio-Vascular Disease, patients who would otherwise go undetected.<br />EndoPAT studies tell you if treatment is effective.<br />Improved patient monitoring and early detection means increased patient compliance with pharmaceutical treatment and lifestyle recommendations.<br />Available and simple financing<br />High Return on Investment<br />
Endopat2000 in the news<br />Fox News Clip<br />